Patents by Inventor Nicholas Van Bruggen

Nicholas Van Bruggen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20230063741
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: April 15, 2022
    Publication date: March 2, 2023
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteins
    Patent number: 11136365
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: October 5, 2021
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen
  • Pharmaceutical compositions of IL-22 Fc fusion proteins
    Patent number: 10584155
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 10, 2020
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190233491
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: September 11, 2018
    Publication date: August 1, 2019
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177388
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177386
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177389
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177390
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20190177387
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 20, 2018
    Publication date: June 13, 2019
    Inventors: Justin Scheer, Wenjun Ouyang, Richard Vandlen, Philip E. Hass, Eric Gary Stefanich, Ganesh A. Kolumam, Xiaoting Wang, Jed Ross, Nicholas Van Bruggen, Wyne P. Lee
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20180362608
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: November 2, 2017
    Publication date: December 20, 2018
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20170320926
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: March 9, 2017
    Publication date: November 9, 2017
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20170088596
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 30, 2017
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
    Publication number: 20170008942
    Abstract: The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.
    Type: Application
    Filed: July 22, 2016
    Publication date: January 12, 2017
    Inventors: Justin SCHEER, Wenjun OUYANG, Richard VANDLEN, Philip E. HASS, Eric Gary STEFANICH, Ganesh A. KOLUMAM, Xiaoting WANG, Jed ROSS, Nicholas VAN BRUGGEN, Wyne P. LEE
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20140363432
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 11, 2014
    Applicant: GENENTECH, INC.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • Vascular endothelial cell growth factor antagonists and uses thereof
    Patent number: 8287873
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Grant
    Filed: April 25, 2008
    Date of Patent: October 16, 2012
    Assignee: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20120237514
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 20, 2012
    Applicant: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • Vascular endothelial cell growth factor antagonists and uses thereof
    Patent number: 8007799
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: August 30, 2011
    Assignee: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • Vascular endothelial cell growth factor antagonists and uses thereof
    Patent number: 7998931
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Grant
    Filed: April 21, 2008
    Date of Patent: August 16, 2011
    Assignee: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • METHOD TO IDENTIFY A PATIENT WITH AN INCREASED LIKELIHOOD OF RESPONDING TO AN ANTI-CANCER AGENT
    Publication number: 20110064670
    Abstract: The invention provides methods for identifying patients having an increased likelihood of responding to an anti-cancer agent or an increased likelihood of undergoing metastasis. The invention also provides methods for monitoring a patients' response to an anti-cancer agent. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 17, 2011
    Applicant: Genentech, Inc.
    Inventors: Alvin Gogineni, Maresa Caunt, Nicholas van Bruggen, Anil D. Bagri, Robby Weimer
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20080311118
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Application
    Filed: April 25, 2008
    Publication date: December 18, 2008
    Applicant: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara